Candel Therapeutics, Inc.
General ticker "CADL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $181.7M (TTM average)
Candel Therapeutics, Inc. follows the US Stock Market performance with the rate: 0.5%.
Estimated limits based on current volatility of 4.9%: low 4.61$, high 5.08$
Factors to consider:
- Total employees count: 38 as of 2024
- Top business risk factors: Regulatory and compliance, Liquidity and credit risks, Labor/talent shortage/retention, Strategic risks and growth management, Infrastructure disruption
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.47$, 11.33$]
- 2025-12-31 to 2026-12-31 estimated range: [3.00$, 8.12$]
Financial Metrics affecting the CADL estimates:
- Negative: with PPE of -4.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.93 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: 0.01 < Interest expense per share per price, % of 0.77
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term CADL quotes
Long-term CADL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.12MM | $0.00MM | $0.00MM |
| Operating Expenses | $34.85MM | $38.39MM | $33.37MM |
| Operating Income | $-34.72MM | $-38.39MM | $-33.37MM |
| Non-Operating Income | $15.93MM | $0.45MM | $-21.81MM |
| Interest Expense | $1.71MM | $2.60MM | $2.09MM |
| R&D Expense | $20.79MM | $24.51MM | $19.31MM |
| Income(Loss) | $-18.79MM | $-37.94MM | $-55.18MM |
| Profit(Loss)* | $-18.79MM | $-37.94MM | $-55.18MM |
| Stockholders Equity | $47.71MM | $12.74MM | $66.33MM |
| Assets | $77.69MM | $41.20MM | $106.87MM |
| Operating Cash Flow | $-31.42MM | $-34.24MM | $-27.02MM |
| Capital expenditure | $1.30MM | $0.46MM | $0.02MM |
| Investing Cash Flow | $-1.30MM | $-0.28MM | $-0.02MM |
| Financing Cash Flow | $19.97MM | $-0.12MM | $94.28MM |
| Earnings Per Share** | $-0.65 | $-1.31 | $-1.74 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.